192. Zhonghua Zhong Liu Za Zhi. 2018 Jul 23;40(7):506-511. doi:10.3760/cma.j.issn.0253-3766.2018.07.005.[Clinical outcome of receptor expression discordance between primary andmetastatic breast cancer].[Article in Chinese; Abstract available in Chinese from the publisher]Mu YX(1), Zhang P(1), Ma F(1), Yuan P(1), Wang JY(1), Xu BH(1), Li Q(1).Author information: (1)Department of Oncology, National Cancer Center/National Clinical ResearchCenter for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China.Objective: To investigate the clinical outcome of expression discordance ofestrogen receptor (ER), progesterone receptor (PR) and human epidermal growthfactor receptor 2 (HER-2) in primary breast cancer and the correspondingmetastatic lesions. Methods: A retrospective analysis was performed on 178 breastcancer patients with metastasis confirmed by the National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences in the past 6 years. The data ofexpressions of ER, PR and HER-2 in primary and metastatic breast cancer, themetastatic sites, disease progression were collected and the relationships of theexpression discordance of receptors with prognosis were analyzed. Results: Thediscordance rates of ER, PR and HER-2 between the primary tumor and themetastatic sites were 27.0%, 39.8% and 18.7%, respectively. The discordance ratesof ER, PR and HER-2 of patients with locoregional recurrence were 21.9%, 36.6%and 12.7%, respectively, while those of patients with distant metastases were31.3%, 42.7% and 23.8%. The median progression free survivals (PFS) ofER+/+、ER+/-、ER-/+、ER-/- of primary tumor and metastatic sites were 17.7 months,10.3 months, 14.0 months and 9.0months, respectively (P=0.025). The median PFS ofPR+/+, PR+/-, PR-/+, PR-/- were 23.0 months, 10.7 months, 14.0 months and9.2months, respectively (P=0.002). The median PFS of HER-2+/+, HER-2+/-,HER-2-/+, HER-2-/- were 14.9 months, 15.2 months, 12.3 months and 14.0 months,respectively, without significant differences (P=0.588). Conclusions: This study confirms that expression discordances of ER, PR and HER-2 between primary breast cancer and the corresponding metastatic lesions are dramatic, especially in thepatients with distant metastasis. The unstable levels of ER and PR seem to besignificantly associated with prognosis of breast patients.Publisher: 目的： 探讨雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)在乳腺癌原发灶和转移灶的异质性及其对患者预后的影响。 方法：回顾性分析2010年5月至2016年6月间中国医学科学院肿瘤医院收治的178例行乳腺癌转移灶活检患者的临床资料，分析ER、PR和HER-2在乳腺癌原发灶和转移灶的表达情况、转移部位、疾病进展情况和受体表达异质性与患者预后的关系。 结果：全组患者ER、PR和HER-2在原发灶和转移灶中表达的不一致率分别为27.0%、39.8%和18.7%；在局部复发转移患者中，ER、PR和HER-2表达的不一致率分别为21.9%、36.6%和12.7%；在远处转移患者中，ER、PR和HER-2表达的不一致率分别为31.3%、42.7%和23.8%。ER原发灶阳性转移灶阳性、原发灶阳性转移灶阴性、原发灶阴性转移灶阳性和原发灶阴性转移灶阴性患者的无进展生存时间(PFS)分别为17.7、10.3、14.0和9.0个月，差异有统计学意义(P=0.025)；PR原发灶阳性转移灶阳性、原发灶阳性转移灶阴性、原发灶阴性转移灶阳性和原发灶阴性转移灶阴性患者的中位PFS分别为23.0、10.7、14.0和9.2个月，差异有统计学意义(P=0.002)；HER-2原发灶阳性转移灶阳性、原发灶阳性转移灶阴性、原发灶阴性转移灶阳性和原发灶阴性转移灶阴性患者的中位PFS分别为14.9、15.2、12.3和14.0个月，差异无统计学意义(P=0.588)。 结论：乳腺癌原发灶和转移灶中ER、PR和HER-2受体表达存在异质性，在远处转移患者中较局部复发转移患者多见，激素受体的改变与患者的预后有关。.PMID: 30060358  [Indexed for MEDLINE]